Two review papers consolidate 30 years of research
BUDAPEST, Hungary, July 25, 2024 / Biotech Newswire / -- HYD LLC for Cancer Research and Drug Development (HYD or the Company) today announces two independent review papers in Nutrients - Deuterium-Depleted Water in Cancer Therapy: A Systematic Review of Clinical and Experimental Trials and Frontiers in Pharmacology – The Biological Impact of Deuterium and Therapeutic Potential of Deuterium-depleted Water. These review papers culminate 30 years of research into Deuterium Depleted Water (DDW) and set out the role of Deuterium-Depleted Water (DDW) in regulating cell division and cancer growth.
The review papers, which assessed almost 200 studies, observed that DDW can inhibit the proliferation of different tumor cell lines and suppress the migratory capability of cancer cells, the cause of metastases, and the spread of cancer through the body. Furthermore, DDW can cause changes to cell cycle regulation, including promoting autophagy, apoptosis, and senescence. More specifically, the review papers identified a series of genes, some upregulated, others downregulated by DDW. The cited prospective and retrospective clinical studies show complete and partial tumor regression, longer survival, and a sharp reduction of cancer recurrence.
The proposed mechanism of action for DDW in cancer is based on the different isotopic properties of Hydrogen (H) and Deuterium (D), the latter of which has not only one proton but also a neutron in its nucleus. Owing to the 100% mass difference between H and D, the two isotopes behave differently in chemical reactions, e.g., D bonds are stronger than H bonds. In water (H2O) and indeed all molecules, the hydrogen (H) bonds break 8-10x more readily than deuterium (D) bonds.
As such, in certain cellular processes where hydrogen is pumped out of the cell (sodium/hydrogen exchange), there is a preference to eliminate hydrogen over the heavy isotope deuterium. Over time, this results in the accumulation of deuterium atoms in the cell, and the D: H ratio increases. As the concentration of deuterium rises above the threshold level (150 parts per million (ppm)), it triggers cell division(1).
Exacerbating the accumulation of deuterium is the well-defined disruption of mitochondria function that occurs in tumor cells(2,3,4). Mitochondria – the energy production organelles of a cell – have a multi-stage process (called the Szent-Györgyi – Krebs cycle or TCA cycle) for producing energy that can be used by the cell for many processes. However, in tumor cells, the mitochondrial TCA cycle is inhibited, and the natural deuterium-depleting function of mitochondria is damaged. The natural production of deuterium-depleted metabolic water in fully functional mitochondria (in healthy cells), is central to keeping the deuterium levels below the critical threshold.
In HYD’s earlier Phase 2, double-blind, randomized trial, out of 44 patients undergoing conventional cancer therapy for prostate cancer, 22 patients also received DDW over four months, with the remaining 22 patients receiving placebo. The results showed that patients receiving DDW had a significantly greater reduction in prostate size compared to the placebo group – on average, down 160cm3 versus 54cm3.
Furthermore, the one-year survival rates were 20 out of the 22 in the DDW arm of the study but only 13 out of 22 in the placebo group; as such, only two died in the DDW arm and 9 in the placebo group.
Gábor Somlyai, CEO and founder of HYD said: “We are on the cusp of a significant breakthrough in cancer therapy that adopts a novel, first-in-class approach based in quantum physics, rather than the traditional biology or chemistry. Deuterium-depleted water has been shown to regulate a series of genes associated with cancer development, suppressing tumor growth, regulating cell metabolism and proliferation, and potentially reducing the rates of or even preventing cancer. While there is clear evidence of DDW treating cancer as a stand-alone modality, we envisage its application to enhance the efficacy of cancer treatment in combination with other therapies.”
Humanity is now on the verge of translating basic research into safe and effective cancer treatments. HYD is currently seeking investors and/or pharmaceutical companies to conduct a pivotal Phase II/III human clinical study with one of the following tumors: glioblastoma, lung cancer, breast cancer, or prostate cancer. The results from this study—if positive—would pave the route to full regulatory marketing approval for DDW as a cancer treatment.
About HYD LLC for Cancer Research and Drug Development
HYD was established to research, develop, and market pharmaceutical and consumer products based on the proprietary procedure of deuterium depletion, primarily for the prevention and treatment of various kinds of cancer and for exploring new indication fields for the application of deuterium-depleted water (DDW). Different applications of deuterium depletion are protected by international patents.
In the early nineties, Hungarian molecular biologist Gábor Somlyai, PhD recognized that the shortage of deuterium can cause significant changes in living organisms. The most important outcome of his research carried out with deuterium-depleted water (DDW) was that tumor cells proved extremely sensitive to deuterium withdrawal (D). Deuterium depletion is a completely original approach to inhibit the growth of cancer cells in the body, and according to the latest results, it can also influence other physiological processes like glucose metabolism.
Recently, the pharmaceutical industry started to develop and commercialize deuterium-containing medicines. Strategic replacement of hydrogen atoms in therapeutics with deuterium could positively influence drug efficacy and side effect profiles.
HYD's approach to deuterium depletion of water and other molecules has broad potential to enhance the effectiveness of the presently available oncotherapies and result in innovative new medicines and consumer products for the treatment and prevention of cancer and other (e.g. metabolic) diseases.
About Deuterium-Depleted Water
Water molecules are comprised of two Hydrogen atoms and one Oxygen – H2O. However, stable, non-radioactive hydrogen comes in two forms (isotopes): normal hydrogen (H), with one proton in the nucleus; and deuterium (D), with one proton AND one neutron in the nucleus. Deuterium is a rare form of hydrogen, and in naturally occurring water only around 150 water molecules per million (ppm) contain deuterium (16.8 mmol/L); the remainder is normal hydrogen. Deuterium-Depleted Water (DDW) has reduced the concentration of deuterium water molecules (HDO) to below 150 parts per million (ppm). HYD creates a range of DDWs, under the brand name Preventa, with concentrations as low as 25 ppm of deuterium.
Contact
HYD LLC
Gábor Somlyai, CEO
This email address is being protected from spambots. You need JavaScript enabled to view it.
References:
- G. Somlyai, G. Jancsó, G. Jákli, K. Vass, B. Barna, V. Lakics és T. Gaál, „Naturally occurring deuterium is essential for the normal growth rate of cells,” FEBS Lett., 317, pp. 1-4, 1993.https://pubmed.ncbi.nlm.nih.gov/8428617/
- Robert L. Elliott, Xian P. Jiang, Jonathan F. Head, Want to Cure Cancer? Then Revisit the Past; “Warburg Was Correct” , Cancer Is a Metabolic Disease, Journal of Cancer Therapy, 2014, 5, 297- 305 Disease https://www.scirp.org/pdf/JCT_2014032510513048.pdf
- Seyfried TN, Flores RE, Poff AM, D'Agostino DP. Cancer as a metabolic disease: implications for novel therapeutics. Carcinogenesis. 2014 Mar;35(3):515-27. doi: 10.1093/carcin/bgt480. Epub 2013 Dec 16. PMID: 24343361; PMCID: PMC3941741. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3941741/
- G. Somlyai. Deuterium depletion – A New Way in Curing Cancer and Preserve Health (Amazon.com)
Keywords: Cytostatic Agents; Deuterium; Cisplatin; gemcitabine; Hydrogen; Mutation Rate; Water; Deoxycytidine; Pancreatic Carcinoma; Pancreatic Neoplasms; Drug Development; Mutagenesis; Food Industry; Cell Line, Tumor; Pharmaceutical Preparations; In Vitro Techniques; Hungary; Deuterium Depletion; Cancer Therapy; HYD LLC; Review Papers; Frontiers in Pharmacology; Deuterium-Depleted Water (DDW); Cell Division Regulation; Cancer Growth Suppression; Clinical and Experimental Trials; Tumor Cell Lines; Metastases; Cell Cycle Regulation; Autophagy; Apoptosis; Senescence; Gene Regulation; Hydrogen (H); Deuterium (D); Isotopic Properties; Sodium/Hydrogen Exchange; Mitochondria Function; Metabolic Water; Gábor Somlyai; Gene Suppression; Cell Metabolism; Proliferation; Cancer Treatment Enhancement; Phase II/III Clinical Study; Glioblastoma; Lung Cancer; Breast Cancer; Prostate Cancer; Regulatory Approval
Source: Biotech Newswire